Lactic acid/citric acid/potassium bitartrate

Lactic acid/citric acid/potassium bitartrate
Combination of
Lactic acidAlpha hydroxy acid
Citric acidTricarboxylic acid
Potassium bitartrateSugar acid salt
Clinical data
Trade namesPhexxi
AHFS/Drugs.comMultum Consumer Information
License data
Routes of
administration		Intravaginal
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Lactic acid/citric acid/potassium bitartrate, sold under the brand name Phexxi, is a non-hormonal combination medication used as a method of birth control.[1][2] It contains lactic acid, citric acid, and potassium bitartrate.[1][2] It is a gel inserted into the vagina.[2][3]

The most common adverse reactions include vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain.[2]

Medical uses

The combination is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.[2]

History

The combination was approved for medical use in the United States in May 2020.[2][4][5]

References

  1. ^ a b c "Phexxi- lactic acid, l-, citric acid monohydrate, and potassium bitartrate gel". DailyMed. Retrieved 13 February 2022.
  2. ^ a b c d e f g "U.S. FDA Approves Evofem Biosciences' Phexxi (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy". Evofem Biosciences (Press release). 22 May 2020. Retrieved 22 May 2020 – via PR Newswire.
  3. ^ Steinberg J, Lynch SE (May 2021). "Lactic Acid, Citric Acid, and Potassium Bitartrate (Phexxi) Vaginal Gel for Contraception". American Family Physician. 103 (10): 628–629. PMID 33982994.
  4. ^ "Phexxi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 23 May 2020.
  5. ^ "Drug Approval Package: Phexxi". U.S. Food and Drug Administration (FDA). 3 November 2020. Retrieved 13 February 2022.